Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointments of Jill Hopkins, M.D., as Chief Medical Officer, President of Research & Development, and Mark Plavsic, Ph.D., as Chief Technology Officer. The Company also announced that Cadmus Rich, M.D., will step down as Chief Medical Officer and assume a new role wi